These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32744395)

  • 21. InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.
    Battelino T; Bosnyak Z; Danne T; Mukherjee B; Edelman S; Pilorget V; Choudhary P; Renard E; Bergenstal R
    Diabetes Ther; 2020 Apr; 11(4):1017-1027. PubMed ID: 32100192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Durability of Basal Insulin Affects Day-to-Day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial.
    Iuchi H; Sakamoto M; Matsutani D; Suzuki H; Horiuchi R; Utsunomiya K
    Diabetes Technol Ther; 2017 Aug; 19(8):457-462. PubMed ID: 28605286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes.
    Oya J; Nakagami T; Hasegawa Y; Katamine A; Kondo Y; Babazono T
    J Diabetes Investig; 2021 Nov; 12(11):1983-1991. PubMed ID: 33938149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
    Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
    Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
    Birkeland KI; Home PD; Wendisch U; Ratner RE; Johansen T; Endahl LA; Lyby K; Jendle JH; Roberts AP; DeVries JH; Meneghini LF
    Diabetes Care; 2011 Mar; 34(3):661-5. PubMed ID: 21270174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous Glucose Monitoring-Derived Glucometrics in Adults with Type 1 Diabetes When Switching Basal Insulins.
    De Groote R; Lefever E; Charleer S; Donné P; Block C; Mathieu C; Gillard P
    Diabetes Technol Ther; 2024 Aug; 26(8):587-595. PubMed ID: 38512387
    [No Abstract]   [Full Text] [Related]  

  • 28. Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial.
    Iga R; Uchino H; Kanazawa K; Usui S; Miyagi M; Kumashiro N; Yoshino H; Ando Y; Hirose T
    Diabetes Ther; 2017 Aug; 8(4):783-792. PubMed ID: 28547206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats.
    Gilor C; Culp W; Ghandi S; do Carmo Emidio E Silva JA; Ladhar A; Hulsebosch SE
    Domest Anim Endocrinol; 2019 Oct; 69():19-29. PubMed ID: 31280022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.
    Weatherall J; Bloudek L; Buchs S
    Curr Med Res Opin; 2017 Feb; 33(2):231-238. PubMed ID: 27764979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Switching insulin degludec to insulin glulisine improved nocturnal hypoglycemia and ventricular arrythmia in an elderly type 1 diabetes patient with chronic heart failure: A case report].
    Hajika Y; Kawaguchi Y; Tanaka T; Hamazaki K; Kumeda Y
    Nihon Ronen Igakkai Zasshi; 2022; 59(2):237-243. PubMed ID: 35650058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice.
    Carral San Laureano F; Tomé Fernández-Ladreda M; Jiménez Millán AI; García Calzado C; Ayala Ortega MDC
    J Investig Med; 2021 Jun; 69(5):983-988. PubMed ID: 33771843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
    Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL
    Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
    Haluzík M; Cheng A; Müller-Wieland D; Westerbacka J; Bosnyak Z; Lauand F; Melas-Melt L; Karalliedde J; Rosenstock J; Bolli GB
    Diabetes Obes Metab; 2020 Aug; 22(8):1369-1377. PubMed ID: 32243043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GlucoTab-guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalized patients with type 2 diabetes.
    Aberer F; Lichtenegger KM; Smajic E; Donsa K; Malle O; Samonigg J; Höll B; Beck P; Pieber TR; Plank J; Mader JK
    Diabetes Obes Metab; 2019 Mar; 21(3):584-591. PubMed ID: 30328252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
    Lüdemann J; Milek K; Wilhelm B; Segner A; Jaeckel E
    MMW Fortschr Med; 2014 Oct; 156 Suppl 3():89-97. PubMed ID: 25507175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
    DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
    Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.